LAUSR

Since global COVID-19 spread worldwide, invasive fungal rhinosinusitis (IFRS) emerged in immunocompromised patients as a new clinical challenge. In this study, clinical specimens of eighty-nine COVID-19 patients who presented clinical and radiological evidence suggestive of IFRS, were examined by direct microscopy, histopathology, and culture, and the isolated colonies were identified through DNA sequence analysis. Fungal elements were microscopically observed in 84.27% of the patients. Males (53.9%) and patients over 40 (95.5%) were more commonly affected than others. Headache (94.4%) and retro-orbital pain (87.6%) were the most common symptoms, followed by ptosis/proptosis/eyelid swelling (52.8%), and 74 patients underwent surgery and debridement. The most common predisposing factors were steroid therapy (n = 83, 93.3%), diabetes mellitus (n = 63, 70.8%), and hypertension (n = 42, 47.2%). The culture was positive for 60.67% of the confirmed cases, and Mucorales were the most prevalent (48.14%) causative fungal agents. Different species of Aspergillus (29.63%) and Fusarium (3.7%) and a mix of two filamentous fungi (16.67%) were other causative agents. For 21 patients, no growth was seen in culture despite a positive result on microscopic examinations. In PCR-sequencing of 53 isolates, divergent fungal taxons including eight genera and 17 species, were identified as followed: Rhizopus oryzae (n = 22), Aspergillus flavus (n = 10), Aspergillus fumigatus (n = 4), Aspergillus niger (n = 3), Rhizopus microsporus (n = 2), Mucor circinelloides, Lichtheimia ramosa, Apophysomyces variabilis, Aspergillus tubingensis, Aspergillus alliaceus, Aspergillus nidulans, Aspergillus calidoustus, Fusarium fujikuroi/proliferatum, Fusarium oxysporum, Fusarium solani, Lomentospora prolificans and Candida albicans (each n = 1). In conclusion, a diverse set of species involved in COVID-19-associated IFRS was observed in this study. Our data encourage specialist physicians to consider the possibility of involving various species in IFRS in immunocompromised and COVID-19 patients. In light of utilizing molecular identification approaches, the current knowledge of microbial epidemiology of invasive fungal infections, especially IFRS, may change dramatically.